A multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase II trial comparing adjuvant treatment with 177Lu-DOTATATE to standard of care in patients after resection of neuroendocrine liver metastases (NELMAS).
Frilling A, Baum R, Veselkov K, Martinez Del Peral E, Martinez M, Lovelle M, Wu J, Park S, Clift A, Eccles A, Hubber J, Wasan H, Modlin I. A multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase II trial comparing adjuvant treatment with 177Lu-DOTATATE to standard of care in patients after resection of neuroendocrine liver metastases (NELMAS). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps4225.Peer-Reviewed Original ResearchGastro-entero-pancreatic neuroendocrine tumorsNeuroendocrine liver metastasesDisease-free survivalStandard of careGastro-entero-pancreaticResection of LMNeuroendocrine tumorsLu-DOTATATEOverall survivalTumor recurrenceLiver resectionAdjuvant treatmentResection of neuroendocrine liver metastasesEarly detection of recurrent diseaseEfficacy of adjuvant therapyPeptide receptor radionuclide therapyDetection of recurrent diseaseDisease-free survival probabilityAssociated with favorable overall survivalStandard of care armAdjuvant treatment conceptsGa-DOTATATE PET/CTLiver-directed therapiesMacroscopic complete resectionProspective open-label
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply